´ëÇÑ´ç´¢º´ÇÐȸ 2022 International Congress of Diabetes and Metabolism(3ÀÏÂ÷) : 2022-10-08±³À°ÀÏÀÚ : 2022-10-08
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ
±³À°ÁÖÁ¦ :
(¿Â-¿ÀÇÁº´Çà) 2022 International Congress of Diabetes and Metabolism(3ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 430,000¿ø
ºñ°í »çÀü: ¿ÀÇÁ¶óÀÎ-ÀÇ»ç ȸ¿ø:25¸¸¿ø »çÀü: ¿ÀÇÁ¶óÀÎ-ÀÇ»ç ºñȸ¿ø:32¸¸¿ø »çÀü: ¿ÀÇÁ¶óÀÎ-ºñÀÇ»ç ȸ¿ø:15¸¸¿ø »çÀü: ¿ÀÇÁ¶óÀÎ-ºñÀÇ»ç ºñȸ¿ø:20¸¸¿ø »çÀü: ¿Â¶óÀÎ-ÀÇ»ç ȸ¿ø:20¸¸¿ø »çÀü: ¿Â¶óÀÎ-ÀÇ»ç ºñȸ¿ø:27¸¸¿ø »çÀü: ¿Â¶óÀÎ-ºñÀÇ»ç ȸ¿ø:10¸¸¿ø »çÀü: ¿Â¶óÀÎ-ºñÀÇ»ç ºñȸ¿ø:15¸¸¿ø ÇöÀå: ¿ÀÇÁ¶óÀÎ-ÀÇ»ç ȸ¿ø:35¸¸¿ø ÇöÀå: ¿ÀÇÁ¶óÀÎ-ÀÇ»ç ºñȸ¿ø:43¸¸¿ø ÇöÀå: ¿ÀÇÁ¶óÀÎ-ºñÀÇ»ç ȸ¿ø:20¸¸¿ø ÇöÀå: ¿ÀÇÁ¶óÀÎ-ºñÀÇ»ç ºñȸ¿ø:25¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 09:00~09:30 Diagnosis of classic type 1 diabetes and LADA Sang-Man Jin(Sungkyunkwan University Korea)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 09:30~10:00 Update on CGM and connected insulin pens in type 1 diabetes Jee Hee Yoo(Yonsei Wonju University Korea)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 10:00~10:30 Highlights from the international consensus meeting on recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice Revital Nimri(Schneider Children¡¯s Medical Center of Israel Israel)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 10:30~11:00 Adjunctive therapy in type 1 diabetes (metformin, GLP-1RA, SGLT2i) Jae Hyun Bae(Korea University Korea)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 11:20~12:00 Preventing type 2 diabetes: back to the future Vanita R. Aroda(Brigham and Women¡¯s Hospital Harvard Medical School USA)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 12:20~13:30 Optimal clinical approach for the management of diabetes and chronic complications with SGLT2-inhibitor Mark Cooper(Monash University Australia)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 13:30~14:00 Renal Benefit of Tirzepatide Hiddo Lambers Heerspink(University Medical Center Groningen Netherlands)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 14:00~14:30 Cag-Sema combination Jaehan Jeon(Kyungpook National University Korea)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 14:30~15:00 When they go low, we go high _ GLP-1/Glucagon Dual Agonisttide Seungjae Baek(Hanmi Pharmaceutical Korea)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 15:00~15:30 The novel GIP, GLP-1, and glucagon triple receptor agonist LY3437943: From discovery to clinical proof-of-concept Tamer Coskun(Eli Lilly and Company USA)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 15:30~16:00 EASD/ESC Symposium: new perspectives on heart function and failure in diabetes Javed Butler(University of Mississippi USA)
±³À°½Ã°£ 10-08 ½ºÀ§½º±×·£µåÈ£ÅÚ Convention Hall A, 4F 16:00~16:30 New insights to prevention of microvascular complications? Christoph Wanner(University Hospital Wuerzburg Germany)